These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17223910)

  • 21. Hydroxyurea in very young children with sickle cell anemia is not a cure-all.
    Powars DR
    J Pediatr; 2001 Dec; 139(6):763-4. PubMed ID: 11743496
    [No Abstract]   [Full Text] [Related]  

  • 22. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
    Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
    J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa.
    Galadanci NA; Kanter J
    Lancet Haematol; 2024 Jun; 11(6):e393-e395. PubMed ID: 38701813
    [No Abstract]   [Full Text] [Related]  

  • 24. Hydroxycarbamide reduces eosinophil adhesion and degranulation in sickle cell anaemia patients.
    Pallis FR; Conran N; Fertrin KY; Olalla Saad ST; Costa FF; Franco-Penteado CF
    Br J Haematol; 2014 Jan; 164(2):286-95. PubMed ID: 24383847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospects for primary stroke prevention in children with sickle cell anaemia.
    Jordan LC; Casella JF; DeBaun MR
    Br J Haematol; 2012 Apr; 157(1):14-25. PubMed ID: 22224940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effectiveness and acceptance of hydroxyurea in the treatment of severe forms of sickle cell disease: a prospective study of 65 cases].
    Mellouli F; Chouaibi S; Dhouib N; Ouederni M; Ben Khaled M; Abbes S; Bejaoui M
    Tunis Med; 2013; 91(8-9):544-50. PubMed ID: 24227514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of clinical response by hydroxyurea in 132 patients with major sickle cell anemia].
    Elira Dokekias A; Okandze Elenga JP; Ndinga J; Sanogo I; Sangare A
    Tunis Med; 2005 Jan; 83(1):32-7. PubMed ID: 15881719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study of hemoglobinopathies found in Belgium].
    Fondu P
    Bull Mem Acad R Med Belg; 1995; 150(10-11):367-75; discussion 376-8. PubMed ID: 8845787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Management of sickle cell disease].
    de Montalembert M
    Rev Prat; 2004 Sep; 54(14):1557-64. PubMed ID: 15558966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating sickle cell anaemia with hydroxycarbamide.
    Pollack S
    Br J Haematol; 2014 Jan; 164(2):296-7. PubMed ID: 24116862
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
    Vicari P; Barretto de Mello A; Figueiredo MS
    Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
    Ware RE; Zimmerman SA; Sylvestre PB; Mortier NA; Davis JS; Treem WR; Schultz WH
    J Pediatr; 2004 Sep; 145(3):346-52. PubMed ID: 15343189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.
    Narang I; Kadmon G; Lai D; Dhanju S; Kirby-Allen M; Odame I; Amin R; Lu Z; Al-Saleh S
    Ann Am Thorac Soc; 2015 Jul; 12(7):1044-9. PubMed ID: 25970812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxyurea for the treatment of sickle cell anemia.
    Platt OS
    N Engl J Med; 2008 Mar; 358(13):1362-9. PubMed ID: 18367739
    [No Abstract]   [Full Text] [Related]  

  • 36. New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.
    Gaziev J; Isgrò A; Mozzi AF; Petain A; Nguyen L; Ialongo C; Dinallo V; Sodani P; Marziali M; Andreani M; Testi M; Paciaroni K; Gallucci C; De Angelis G; Alfieri C; Ribersani M; Lucarelli G
    Pediatr Blood Cancer; 2015 Apr; 62(4):680-6. PubMed ID: 25557687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
    Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
    Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of sickle cell disease from childhood through adulthood.
    Kanter J; Kruse-Jarres R
    Blood Rev; 2013 Nov; 27(6):279-87. PubMed ID: 24094945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
    Anderson N
    Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.